On November 26th- 28th, The 5th World Precision Medicine (China) Summit (WPMCS)2020 was successfully launched in Shanghai.Nanodigmbio made a keynote speech titled Continuous Improvement and Optimization on Target Sequencing for Precision Oncology, which focused on the development of Optimization on Targeted Sequencing and application in Precision Oncology.
Focusing on the precise diagnosis and precise treatment, the conference set up two simultaneous conferences: The 5th Genetic Testing & IVD Forum 2020 and The 5th Cell Therapy Innovation Forum 2020. More than 100 domestic and foreign scientists gave keynote speeches and shared the latest academic achievements. Nanodigmbio Technology was invited to deliver one keynote speech, illustrating our latest research progress in targeted sequencing.
The capture-based targeted sequencing is one of the key tools in precision medicine. The way to achieve better gene enrichment and lower sequencing cost by distinguishing and optimizing the design for specific population, samples and even targeted areas (such as MSI, SNP) is the direction of Naondigmbio's persistent goals.
At the meeting, Naondigmbio firstly announced the multi-purpose HiSNP Panel covered up to 50000 SNP sites and shared its specific design concept. On the premise of uniform distribution of the whole genome, the panel optimizes SNP sites with high AF according to the Chinese population. Combined with the unique algorithm, the panel can achieve highly efficient capture performance and can be used in various applications, such as copy number variation analysis and HRD evaluation.
As a company specialized in NGS, Nanodigmbio Technology has total solutions for both MGI platforms and illumina® platforms. Nanodimbio owns over 2,000㎡ of R&D center and over 2,500㎡ of GMP manufacturing facility. Nanodigmbio will continue to provide outstanding products and satisfactory services for customers from research institutions and industry organizations.